Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central Precocious Puberty

Table 1

Initial clinical/hormonal characteristics of the patients and treatment dose (mean ± SD) (range).

	CPP ()	RP-PP ()	AP ()
Chronological age (years)	6.7 ± 1.1 (4.3–8.5)	7.9 ± 1.1 (4.5–9.4)	9.3 ± 0.5 (8.5–10.1)
Bone age (years)	7.7 ± 1.4 (4.1–10.0)	9.7 ± 1.4 (6.8–11.1)	11.2 ± 1.2 (8.8–12.0)
BMI SDS	0.5 ± 1.0 (−1.3–2.8)	1.0 ± 0.8 (−0.9–2.6)	0.9 ± 0.8 (−0.3–3.3)
Stage of puberty (median) (range)	2 (2-3)	3 (2-3)	3 (2–5)
Basal LH (mIU/mL)	0.2 ± 0.3 (0.1–1.5)	0.8 ± 0.9 (0.1–2.9)	2.6 ± 2.3 (0.1–10.3)
Peak LH (mIU/mL)	8.0 ± 5.1 (5.3–27.1)	9.8 ± 11.1 (5.0–48.8)	17.6 ± 12.4 (9.8–32.0)
E2 (pg/mL)	20.4 ± 11.7 (3.8–54.9)	25.3 ± 11.7 (17–51.3)	37.7 ± 15.9 (20.0–68.7)
Leuprolide acetate dose (mg/kg/28 days)	0.14 ± 0.03 (0.11–0.23)	0.12 ± 0.02 (0.09–0.19)	0.09 ± 0.01 (0.04–0.13)

CPP: central precocious puberty, RP-PP: rapidly progressive precocious puberty, AP: advanced puberty, BMI: body mass index, and SDS: standard deviation score.